Q1 2026 · 13F-HR
Vestal Point Capital, LPholdings as filed
Filed 2026-05-15 · accession 0001974915-26-000004
$3.58B
Reported value
90
Positions
2026-03-31
Period end
The Brief · Vestal Point Capital, LP · Q1 2026
AI · grounded in 13F
Vestal Point Capital, LP exited its position in Invesco QQQ Trust Series 1 QQQ, reducing exposure by $215M. The fund also closed positions in Arcellx Inc ACLXGBX for $190.7M and Dexcom Inc DXCM for $84.6M. On the buy side, the fund established a new position in Neurocrine Biosciences Inc NBIX worth $164.7M and increased its holdings in Repligen Corp RGEN by 1,014.46%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 76155X100 | RVMD | Revolution Medicines Inc | $231.0M | 6.46% | 2,375,000 | Common | SOLE |
| 09061G101 | BMRN | BioMarin Pharmaceutical Inc | $202.0M | 5.65% | 3,575,000 | Common | SOLE |
| 00370M103 | ABVX | Abivax SA | $167.0M | 4.67% | 1,500,000 | Common | SOLE |
| 64125C109 | NBIX | Neurocrine Biosciences Inc | $164.7M | 4.60% | 1,250,000 | Common | SOLE |
| 04280A100 | ARWR | Arrowhead Pharmaceuticals Inc | $142.6M | 3.99% | 2,275,000 | Common | SOLE |
| 29337E102 | ELVN | Enliven Therapeutics Inc | $127.4M | 3.56% | 3,250,000 | Common | SOLE |
| 759916109 | RGEN | Repligen Corp | $109.0M | 3.05% | 925,000 | Common | SOLE |
| 055477103 | BCAX | Bicara Therapeutics Inc | $107.9M | 3.02% | 5,425,000 | Common | SOLE |
| 67080M103 | NRIX | Nurix Therapeutics Inc | $100.8M | 2.82% | 6,500,000 | Common | SOLE |
| 03770N101 | APGE | Apogee Therapeutics Inc | $92.6M | 2.59% | 1,100,000 | Common | SOLE |
| 04351P101 | ASNDUSD | Ascendis Pharma A/S | $85.8M | 2.40% | 375,000 | Common | SOLE |
| 45258D105 | IMCR | Immunocore Holdings PLC | $83.4M | 2.33% | 2,766,868 | Common | SOLE |
| 877619106 | TSHA | Taysha Gene Therapies Inc | $80.5M | 2.25% | 18,000,000 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics Inc | $72.5M | 2.03% | 4,000,000 | Common | SOLE |
| 80105N105 | SNY | Sanofi SA | $67.5M | 1.89% | 1,400,000 | Common | SOLE |
| 09058V103 | BCRX | BioCryst Pharmaceuticals Inc | $66.9M | 1.87% | 7,025,000 | Common | SOLE |
| 80706P103 | SRRK | Scholar Rock Holding Corp | $65.1M | 1.82% | 1,324,422 | Common | SOLE |
| N44445109 | IMTX | Immatics NV | $60.8M | 1.70% | 6,175,000 | Common | SOLE |
| 110122108 | BMY | Bristol-Myers Squibb Co | $60.6M | 1.70% | 1,000,000 | Common | SOLE |
| H01301128 | ALC | Alcon AG | $60.3M | 1.69% | 800,000 | Common | SOLE |
| 61225M102 | GLUE | Monte Rosa Therapeutics Inc | $59.3M | 1.66% | 3,603,465 | Common | SOLE |
| 92337R101 | VERA | Vera Therapeutics Inc | $55.0M | 1.54% | 1,368,159 | Common | SOLE |
| 880881107 | 430 | Terns Pharmaceuticals Inc | $52.7M | 1.47% | 1,000,000 | Common | SOLE |
| 379577208 | GMED | Globus Medical Inc | $52.6M | 1.47% | 610,520 | Common | SOLE |
| 101137107 | BSX | Boston Scientific Corp | $50.2M | 1.40% | 800,000 | Common | SOLE |
| 670703107 | NUVL | Nuvalent Inc | $49.4M | 1.38% | 481,715 | Common | SOLE |
| 19240Q201 | COGT | Cogent Biosciences Inc | $47.4M | 1.32% | 1,230,888 | Common | SOLE |
| 02157Q109 | ANRO | Alto Neuroscience Inc | $46.4M | 1.30% | 2,064,075 | Common | SOLE |
| 75383L102 | RAPP | Rapport Therapeutics Inc | $44.9M | 1.26% | 1,436,229 | Common | SOLE |
| 254604101 | IRON | Disc Medicine Inc | $44.8M | 1.25% | 700,000 | Common | SOLE |
| 91307C102 | UTHR | United Therapeutics Corp | $44.5M | 1.24% | 75,000 | Common | SOLE |
| 15117B202 | CLDX | Celldex Therapeutics Inc | $38.8M | 1.09% | 1,224,165 | Common | SOLE |
| 483497103 | KALV | KalVista Pharmaceuticals Inc | $37.2M | 1.04% | 1,850,000 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc | $37.2M | 1.04% | 639,900 | Common | SOLE |
| 83422E204 | SLDB | Solid Biosciences Inc | $36.0M | 1.01% | 5,000,000 | Common | SOLE |
| 10919W405 | DRUG | Bright Minds Biosciences Inc | $35.9M | 1.00% | 492,319 | Common | SOLE |
| 74366E102 | PTGX | Protagonist Therapeutics Inc | $34.4M | 0.96% | 326,159 | Common | SOLE |
| 24823R105 | DNLI | Denali Therapeutics Inc | $34.0M | 0.95% | 1,773,326 | Common | SOLE |
| 75886F107 | REGN | Regeneron Pharmaceuticals Inc | $30.9M | 0.86% | 40,000 | Common | SOLE |
| 941848103 | WAT | Waters Corp | $29.8M | 0.83% | 100,000 | Common | SOLE |
| 92686J106 | VKTX | Viking Therapeutics Inc | $29.7M | 0.83% | 914,147 | Common | SOLE |
| 457730109 | INSP | Inspire Medical Systems Inc | $27.8M | 0.78% | 539,269 | Common | SOLE |
| G2545C104 | CBIO | Crescent Biopharma Inc | $27.6M | 0.77% | 1,500,000 | Common | SOLE |
| 89532M101 | TRVI | Trevi Therapeutics Inc | $25.8M | 0.72% | 2,166,504 | Common | SOLE |
| 52886X107 | LXEO | Lexeo Therapeutics Inc | $25.7M | 0.72% | 4,475,000 | Common | SOLE |
| 834203309 | SLNO | Soleno Therapeutics Inc | $24.4M | 0.68% | 730,000 | Common | SOLE |
| 08659B102 | BBNX | Beta Bionics Inc | $22.2M | 0.62% | 2,211,518 | Common | SOLE |
| 640268306 | NKTR | Nektar Therapeutics | $20.5M | 0.57% | 285,000 | Common | SOLE |
| 23282W605 | CYTK | Cytokinetics Inc | $19.8M | 0.55% | 300,000 | Common | SOLE |
| G0593M107 | AZN | AstraZeneca PLC | $19.7M | 0.55% | 100,000 | Common | SOLE |
| 955306105 | WST | West Pharmaceutical Services I | $18.8M | 0.53% | 75,000 | Common | SOLE |
| 36266G107 | GEHC | GE HealthCare Technologies Inc | $17.8M | 0.50% | 250,000 | Common | SOLE |
| 85220G109 | SGP | SpyGlass Pharma Inc | $17.3M | 0.48% | 666,760 | Common | SOLE |
| 98956P102 | ZBH | Zimmer Biomet Holdings Inc | $17.2M | 0.48% | 190,000 | Common | SOLE |
| 558868105 | MDGL | Madrigal Pharmaceuticals Inc | $16.5M | 0.46% | 31,468 | Common | SOLE |
| 81663L200 | WGS | GeneDx Holdings Corp | $16.1M | 0.45% | 250,000 | Common | SOLE |
| 36322Q206 | DMRA | Damora Therapeutics Inc | $15.5M | 0.43% | 600,000 | Common | SOLE |
| 00847X104 | AGIO | Agios Pharmaceuticals Inc | $15.2M | 0.43% | 450,000 | Common | SOLE |
| 29286M105 | — | enGene Therapeutics Inc | $14.7M | 0.41% | 2,165,000 | Common | SOLE |
| 805111101 | SVRA | Savara Inc | $14.2M | 0.40% | 2,600,052 | Common | SOLE |
| 87650L103 | TARS | Tarsus Pharmaceuticals Inc | $14.0M | 0.39% | 200,000 | Common | SOLE |
| 92915B106 | VYGR | Voyager Therapeutics Inc | $11.6M | 0.32% | 3,002,936 | Common | SOLE |
| 45784P101 | PODD | Insulet Corp | $10.6M | 0.30% | 50,601 | Common | SOLE |
| 878972108 | TECX | Tectonic Therapeutic Inc | $10.1M | 0.28% | 328,000 | Common | SOLE |
| 86889P208 | SRZN | Surrozen Inc | $9.9M | 0.28% | 338,611 | Common | SOLE |
| 04335A105 | ARVN | Arvinas Inc | $9.6M | 0.27% | 905,465 | Common | SOLE |
| 56565P103 | MPLT | MapLight Therapeutics Inc | $8.5M | 0.24% | 420,000 | Common | SOLE |
| 359616109 | FULC | Fulcrum Therapeutics Inc | $8.4M | 0.24% | 1,100,000 | Common | SOLE |
| 68277Q105 | OKUR | OnKure Therapeutics Inc | $7.6M | 0.21% | 1,839,819 | Common | SOLE |
| 62855J104 | MYGN | Myriad Genetics Inc | $7.4M | 0.21% | 1,648,000 | Common | SOLE |
| 68062P106 | OLMA | Olema Pharmaceuticals Inc | $6.4M | 0.18% | 428,551 | Common | SOLE |
| 03675P102 | AVR | Anteris Technologies Global Co | $6.4M | 0.18% | 1,144,780 | Common | SOLE |
| N90064101 | QURE | uniQure NV | $5.9M | 0.16% | 358,996 | Common | SOLE |
| 137404109 | CADL | Candel Therapeutics Inc | $5.5M | 0.15% | 1,125,000 | Common | SOLE |
| 696389402 | PALI | Palisade Bio Inc | $4.4M | 0.12% | 2,500,000 | Common | SOLE |
| 92337F107 | VCYT | Veracyte Inc | $4.2M | 0.12% | 130,687 | Common | SOLE |
| 98937L105 | ZBIO | Zenas Biopharma Inc | $3.9M | 0.11% | 200,000 | Common | SOLE |
| 374163103 | GERN | Geron Corp | $3.8M | 0.11% | 2,540,000 | Common | SOLE |
| 61023L207 | MNPR | Monopar Therapeutics Inc | $3.6M | 0.10% | 65,418 | Common | SOLE |
| G9TY5A101 | ZURA | Zura Bio Ltd | $3.0M | 0.09% | 511,000 | Common | SOLE |
| G6674U108 | NVCR | Novocure Ltd | $2.7M | 0.08% | 250,000 | Common | SOLE |
| B6S7WD106 | NYXH | Nyxoah SA | $2.5M | 0.07% | 868,661 | Common | SOLE |
| M96088105 | URGN | UroGen Pharma Ltd | $2.5M | 0.07% | 139,079 | Common | SOLE |
| 702712209 | PASG | Passage Bio Inc | $2.4M | 0.07% | 305,000 | Common | SOLE |
| 90240B106 | TYRA | Tyra Biosciences Inc | $2.1M | 0.06% | 54,000 | Common | SOLE |
| 75901B107 | RGNX | REGENXBIO Inc | $909,440 | 0.03% | 108,525 | Common | SOLE |
| 88032L605 | TENX | Tenax Therapeutics Inc | $854,490 | 0.02% | 53,439 | Common | SOLE |
| 556099109 | MGNX | MacroGenics Inc | $809,200 | 0.02% | 280,000 | Common | SOLE |
| 00091E109 | ABSI | Absci Corp | $696,657 | 0.02% | 232,219 | Common | SOLE |
| 03836J201 | APRE | Aprea Therapeutics Inc | $267,015 | 0.01% | 350,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.